What is VTVT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.12B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VTVT?

P/E (TTM) is n/a and 52-week range is $19.50 to $44.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VTVT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VTVT?

The company profile lists revenue (TTM) near $12M, net income (TTM) near $8M, EPS (TTM) near $-1.06 when available from the market-data feed. Figures are informational and may lag live markets.

Where is vTv Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in High Point, North Carolina, US, 3.9M shares outstanding, ISIN US9183852048 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

vTv Therapeutics Inc

$VTVT

Health Care · Biotechnology

IR Run Scenarios

$31.18

+3.66%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 26 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Employees

Website

vtvtherapeutics.com/

IPO

2015-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)